Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, presented NeuLogiq® ...

Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer's pTau217 pathology ...

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical ...

All staff members working for a Nottinghamshire hospitals trust must now undergo mandatory dementia training after a ...

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

At this week’s International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, researchers from Suntec Medical Inc. and collaborators presented a poster ...

Worley was part of a team that showed how the loss of one of the two proteins used in the test disrupts synapses and leads to ...

Drew Struzan, best known for painting several iconic Hollywood movie posters, is currently battling Alzheimer's. Struzan's ...

Michael Small, 79, has dementia and went missing on Monday, March 24 around 4:45 p.m. after wandering off at Green Acres ...

Even if you have never heard the name Drew Struzan before now, you have likely seen his impressive work. Struzan is a legendary movie poster artist who has worked on some of the most iconic movie ...

This protein, which can be measured with a blood test, has emerged as an indicator of Alzheimer’s disease pathology. Analysis of this low-p-Tau217 subgroup was defined in the SHINE study design in ...

Secondary endpoints in the MINDFuL trial include the CDR-SB, E-Cog, ADL and Neuropsychiatric Inventory (NPI) instruments, ...